24 Erectile Dysfunction Clinical Trials in Hackensack, NJ (2026)

Q: Are there erectile dysfunction clinical trials in Hackensack?

Yes, there are 24 erectile dysfunction clinical trials currently recruiting in Hackensack, NJ.

Q: How do I join a clinical trial in Hackensack?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you.

Q: Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Erectile Dysfunction Studies in Hackensack

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

Hackensack, NJPHASE1542 participantsSanofi

View Study Details

NCT06764771Recruiting

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tum...

Hackensack, NJPHASE1437 participantsBristol-Myers Squibb

View Study Details

NCT07287995Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then att...

Hackensack, NJPHASE1428 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06792552Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors...

Hackensack, NJPHASE1414 participantsNextCure, Inc.

View Study Details

NCT06697197Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

Hackensack, NJPHASE1413 participantsBristol-Myers Squibb

View Study Details

NCT06730750Recruiting

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5....

Hackensack, NJPHASE1360 participantsBristol-Myers Squibb

View Study Details

NCT05684965Recruiting

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

Hackensack, NJPHASE1358 participantsXilio Development, Inc.

View Study Details

NCT06596473Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in ...

Hackensack, NJPHASE1310 participantsBeOne Medicines

View Study Details

NCT06818643Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumor...

Hackensack, NJPHASE1270 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04145622Recruiting

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

Hackensack, NJPHASE1250 participantsDaiichi Sankyo

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

Hackensack, NJPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT06598800Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and prelim...

Hackensack, NJPHASE1153 participantsBeOne Medicines

View Study Details

NCT06781983Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanc...

Hackensack, NJPHASE1145 participantsInnate Pharma

View Study Details

NCT07104032Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractor...

Hackensack, NJPHASE3132 participantsOno Pharmaceutical Co., Ltd.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

Hackensack, NJPHASE1120 participantsSystImmune Inc.

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

Hackensack, NJ100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT04794686Recruiting

ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes

This research is being done to find out more information about a brain tumor called Embryonal Tumor with Multilayer Rosettes (ETMR) by collecting medical information from children who have this diseas...

Hackensack, NJ100 participantsHackensack Meridian Health

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Hackensack, NJPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT07414836Recruiting

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants...

Hackensack, NJPHASE184 participantsBeOne Medicines

View Study Details

NCT05269316Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

Hackensack, NJPHASE161 participantsImpact Therapeutics, Inc.

View Study Details

NCT07607678Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ...

Hackensack, NJPHASE160 participantsBoehringer Ingelheim

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Hackensack, NJPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT06714864Recruiting

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years o...

Hackensack, NJPHASE436 participantsCorMedix

View Study Details

NCT04865887Recruiting

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is...

Hackensack, NJPHASE235 participantsGeorgetown University

View Study Details

About Erectile Dysfunction Clinical Trials in Hackensack

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 24 erectile dysfunction clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 5,128 participants. Research is being sponsored by Sanofi, Bristol-Myers Squibb, Astellas Pharma Global Development, Inc. and 17 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Hackensack — FAQ

Are there erectile dysfunction clinical trials in Hackensack?

Yes, there are 24 erectile dysfunction clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 24 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated July 21, 2026 from ClinicalTrials.gov